Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that Canalevia-CA1 (crofelemer delayed-release tablets), the company's prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is now available from multiple leading veterinary distributors in the U.S. Canalevia-CA1 received conditional approval from the FDA on December 21, 2021. "We are very excited that Canalevia-CA1 is now available to veterinarians across the country," said Chip Whitlow, Sales & Marketing Director of the company's Animal Health Commercial Portfolio.

Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

SAN FRANCISCO, CA / ACCESSWIRE / April 20, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar's president, founder, and CEO, will present at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino in Hollywood, Florida on Thursday, April 21, 2022, at 11:00 AM Eastern. There is also the opportunity to meet Jaguar management at the company's breakout session scheduled for 10:00 AM Eastern the same day.

Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022

Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA Veterinary oncologists can click here to register for the dinner and tableside discussion SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is hosting a dinner and tableside discussion for U.S. veterinary oncologists in Puerto Vallarta, Mexico from 5:30 PM - 10:00 PM on Tuesday, April 12, 2022, the final day of the Veterinary Cancer Society (VCS) Mid-Year Conference. This exclusive dinner experience will feature a private chef, entertainment, and a tableside discussion on treatment therapies for chemotherapy-induced diarrhea (CID) in dogs.

Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico

Dr. Chaturvedi continues to serve as Chair of company's Scientific Advisory Board Dr. Chaturvedi continues to provide leadership to the development of two crofelemer pipeline indications, with anticipated key milestones in the next 12-15 months. SAN FRANCISCO, CA / ACCESSWIRE / April 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Pravin Chaturvedi, PhD, a pharmaceutical veteran and leading clinical development expert, has been appointed Chief Scientific Officer (CSO) and Chair of the Scientific Advisory Board (SAB) of Jaguar.

Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer

Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 10.90% at $0.70 on continued momentum after the company last week announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer.

Here's Why Jaguar Health Shares Are Rising

BitNile Holdings

Tonix Pharmaceuticals Hld

Check these 3 penny stocks out for your watchlist this month The post Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1

Ambev

Vinco Ventures

Which penny stocks are you watching in April? The post Best Penny Stocks to Buy as March Comes to an End?

Best Penny Stocks to Buy as March Comes to an End? 3 to Check Out

Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 31.2% at $0.70 after the company announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer in the Middle East. Per.

Here's Why Jaguar Health Shares Are Popping Off

Here's the big partnership news that's taking shares of Jaguar Health and JAGX stock soaring in afternoon trading today. The post Why Is Jaguar Health (JAGX) Stock Up Today?

Why Is Jaguar Health (JAGX) Stock Up Today?

Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human indications of crofelemer approved in the U.S., including future target indications SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company has entered an agreement (the "Agreement") with Quadri Pharmaceuticals Store LLC (Quadri Pharma) that grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for specified human indications of crofelemer in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates (UAE), and Oman following regulatory approval to market crofelemer in these countries for the specified indications, including the indication currently approved in the U.S. for HIV-related diarrhea, and cancer therapy-related diarrhea, for which crofelemer is currently in a pivotal Phase 3 clinical trial. In addition, the Agreement grants Quadri Pharma exclusive rights to distribute crofelemer in these countries in the immediate future under Named Patient Programs.

Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q4 2021 Results - Earnings Call Transcript

Click here to access webcast replay Core 2022 development initiatives: Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) Initiation and completion in 2H 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure (SBS-IF) FDA conditional approval in December 2021 of Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea (CID) in dogs Fourth quarter 2021 Mytesi net revenue was approximately $2.1 million versus approximately $0.6 million in the third quarter of 2021, an increase of 230% SAN FRANCISCO, CA / ACCESSWIRE / March 14, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the recording of the company's March 14, 2022, investor webcast regarding company updates and reported consolidated financial results for the year ended December 31, 2021 can be accessed by clicking here . About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea.

Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast

AnPac Bio-Medical Science Co

Ra Medical Systems Inc

Exela Technologies

Reddit penny stocks under $1 to watch this week. The post 5 Penny Stocks Under $1 To Buy According To Redditors This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks Under $1 To Buy According To Redditors This Week

Core 2022 development initiatives: Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) Initiation and completion in 2H 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure (SBS-IF) FDA conditional approval of Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea (CID) in dogs Fourth quarter 2021 Mytesi net revenue was approximately $2.1 million versus approximately $0.6 million in the third quarter of 2021, an increase of 230% REMINDER: Jaguar to host investor webcast Monday, March 14th at 8:30 a.m. Eastern regarding 2021 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / March 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided company updates and reported consolidated financial results for the year ended December 31, 2021.

Jaguar Health Provides Company Updates and Reports 2021 Financials

Click here to register for webcast Company plans to file its Annual Report on March 11, 2022 on Form 10-K for the fiscal year ended December 31, 2021 SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Monday, March 14, 2022, at 8:30 a.m. Eastern Time to review fourth-quarter 2021 financials and provide corporate updates.

Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates

Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA U.S. veterinarians, veterinary oncologists, and members of the media can click here to register for the CID Treatment Forum SAN FRANCISCO, CA / ACCESSWIRE / March 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is hosting a treatment forum for veterinarians about chemotherapy-induced diarrhea (CID) in dogs at the Mandalay Bay Resort and Casino in Las Vegas on Sunday, March 6, 2022 from 5:30 PM - 7:30 PM Pacific Time during the Western Veterinary Conference (WVC), which is being held at the same location. Noted veterinary oncologist Dr. Craig A.

Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas

In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under the name Canalevia™-CA2, for treatment of EID in dogs SAN FRANCISCO, CA / ACCESSWIRE / February 16, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has submitted a request to the U.S. Food and Drug Administration's Center for Veterinary Medicine for Minor Use/Minor Species (MUMS) designation for the company's oral plant-based drug candidate Canalevia™ (crofelemer) for treatment of exercise-induced diarrhea (EID) in dogs. "MUMS designation is a status similar to ‘orphan drug' status for human drugs, and it makes the proposed intended use of a MUMS drug eligible for specific incentives supporting product approval or conditional approval.

Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs

SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business model SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S.p.A., an Italian corporation established by Jaguar Health in Milan, Italy, today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).

Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency

Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has completed filing of the final major regulatory section with the U.S. Food and Drug Administration's ("FDA") Center for Veterinary Medicine (CVM) to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia (crofelemer delayed-release tablets) to treat exercise-induced diarrhea (EID) in dogs. In December of 2021, Jaguar Animal Health received conditional approval from the FDA for Canalevia™-CA1 for chemotherapy-induced diarrhea (CID) in dogs.

Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs

Study results expected to be described in upcoming presentations and publications CDD patients face intestinal failure (IF), similar to patients suffering from short bowel syndrome (SBS) - the priority focus for ODD development for crofelemer SAN FRANCISCO, CA / ACCESSWIRE / February 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) and Napo Pharmaceuticals, the company's wholly owned subsidiary, today announced the completion of a third-party, investigator-initiated preclinical enterocyte (intestinal cell) in vitro study to evaluate the effects of crofelemer,Napo Pharmaceuticals' plant-based prescription drug, on certain genetic defects that result in specific forms of congenital diarrheal disorders. Jaguar Health believes that these study results will support certain requests received from the Office of Orphan Products Development at the U.S. Food and Drug Administration (FDA) in response to the Orphan Drug Designation (ODD) application Napo Pharmaceuticals filed with the FDA for crofelemer for congenital diarrheal disorders (CDD) in infants and children.

Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)

Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has been granted Orphan-Drug Designation for crofelemer by the European Medicines Agency, and Jaguar Health has been granted Orphan-Drug Designation for crofelemer by the FDA SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / January 24, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S.p.A., an Italian corporation established by Jaguar Health in Italy, today announced the appointment of Martire Particco, MD, a physician with 30+ years of experience in Europe's pharmaceutical industry and in clinical practice, as Chief Medical Officer of Napo Therapeutics.

Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics

2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure (SBS-IF) and received conditional approval for Canalevia™-CA1 (crofelemer) for dogs Pipeline advancing in 2022 with company's Phase 3 CTD study continuing and expected completion of an SBS-IF investigator-initiated proof-of-concept trial 2022: Jaguar's year of the dog with continued launch, education, and promotion activity for Canalevia-CA1, which received conditional approval December 21, 2021, for chemotherapy induced diarrhea in dogs SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today provided a corporate update and outlined expected 2022 milestones. "2021 was a year of progress for Jaguar Health as we advanced our key human pipeline initiatives with the presentation at December's San Antonio Breast Cancer Symposium of Phase 2 data for prophylaxis in chemotherapy-related diarrhea; received Orphan Drug Designation in the European Union for crofelemer for short bowel syndrome; formed Napo Therapeutics in Milan, Italy, which was subsequently funded as a result of the merger of Napo Therapeutics with Milan-based Dragon SPAC S.p.A.

Jaguar Health Provides Corporate Update and Outlines 2022 Milestones

China Rapid Finance

Zomedica

Check these three under $1 penny stocks out for your watchlist The post 3 Penny Stocks to Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch Under $1 Right Now

Jaguar Health Inc (NASDAQ:JAGX) shares are trading higher following a Tuesday 13G filing from Oasis Capital showing a 9.99% stake in the company. According to the filing, Oasis Capital has a passive stake of 4,604,484 shares in Jaguar Health.

Why Jaguar Health Shares Are Rising

JAGX stock is rallying on Wednesday after a rough year thanks to news that Oasis Capital has taken a 10% stake in Jaguar Health. The post JAGX Stock Alert: What Is Going on With Jaguar Health Today?

News for Jaguar Health Stock (JAGX)